These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 21987724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
    Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB.
    Proc Natl Acad Sci U S A; 2012 Aug 28; 109(35):14164-9. PubMed ID: 22891331
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
    Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ.
    Cancer Res; 2009 Mar 15; 69(6):2540-9. PubMed ID: 19276385
    [Abstract] [Full Text] [Related]

  • 5. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.
    Clin Exp Pharmacol Physiol; 2013 Jan 15; 40(1):13-21. PubMed ID: 23110505
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.
    Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL.
    Oncogene; 2017 Aug 10; 36(32):4610-4618. PubMed ID: 28368403
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M, Xiao Q, Hu J, Cheng F, Zhang P, Zong W, Tang Q, Li X, Mao F, He Y, Yu X, Wan F, Lei T, Guo D, Wang B.
    Cancer Gene Ther; 2020 Dec 10; 27(12):878-897. PubMed ID: 31988476
    [Abstract] [Full Text] [Related]

  • 13. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
    Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.
    Cancer Discov; 2011 Oct 10; 1(5):442-56. PubMed ID: 22059152
    [Abstract] [Full Text] [Related]

  • 14. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
    Schulte A, Liffers K, Kathagen A, Riethdorf S, Zapf S, Merlo A, Kolbe K, Westphal M, Lamszus K.
    Neuro Oncol; 2013 Oct 10; 15(10):1289-301. PubMed ID: 23877316
    [Abstract] [Full Text] [Related]

  • 15. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
    Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS.
    Cancer Discov; 2011 Nov 15; 1(6):524-38. PubMed ID: 22145100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.